Examining retinal blood vessels to understand systemic diseases
Official title: Retinal Microvascularization in OCT-angiography and Systemic Diseases
Run by Centre Hospitalier Universitaire Dijon · NCT06613555 · Data updated 2026-11-12
This study looks at the tiny blood vessels in the eye to see if they can help us understand and predict chronic inflammatory diseases in people with and without systemic vascular conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Status | Recruiting |
| Started | June 19, 2024 |
| Main results expected | June 2044 |
| Study ends | June 2044 |
| Registry record updated | September 26, 2024 |
| Trial ID | NCT06613555 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with systemic vascular pathology, high cardiovascular risk, inflammatory vascular pathology, or preeclampsia, as well as healthy individuals without systemic or vascular issues.
✕Probably not a fit
Patients with existing ocular diseases or those who do not meet the inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the relationship between retinal microvascularization and systemic vascular damage. It aims to identify predictive indicators of chronic inflammatory diseases by analyzing the health of small blood vessels in the retina using non-invasive imaging techniques. Patients with systemic vascular conditions and healthy controls will be monitored over time to assess the progression of these diseases. The study utilizes retinal imaging and biological check-ups to gather data.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of systemic vascular diseases.
How similar studies have gone: While the approach of using retinal microcirculation as a predictive indicator is promising, it is relatively novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: For the \"patients with systemic vascular disease\" group * Patients who have given oral, free and informed consent * Patients with either : * systemic vascular pathology * high cardiovascular risk * inflammatory vascular pathology * preeclampsia during pregnancy The study will also be offered to patients who have already had an OCT-A examination as part of their routine care, in order to follow them over time. For the \"healthy control\" group * Patients who have given free, oral and informed consent * Patients with no prior systemic or vascular inflammatory pathology, and no high cardiovascular risk * Non-diabetic patients * Pregnant patients with risk-free pregnancies recruited from the gynecology department of CHU Dijon Bourgogne OR * Adult patients without maculopathy recruited from the Ophthalmology Department of CHU Dijon Bourgogne Exclusion Criteria: * For the \"patients with systemic vascular disease\" group * Ophthalmological history in both eyes (vascular and degenerative macular pathologies) * Protected patient : * Minor patient * Patient under legal protection (guardianship, curatorship, court order) * Patient unable to give consent Person not affiliated to a social security scheme * Breast-feeding women * Person with a contraindication to Tropicamide * OCT-A signal strength \< 7 For the \"healthy control\" group * Any pathology studied in the case group * Ophthalmological history in both eyes (vascular and degenerative macular pathologies) * Type 1 or type 2 diabetes * Person with a contraindication to Tropicamide * Protected person : * Minor * Person under legal protection (guardianship, curatorship, court order) * Person unable to give consent * Person not affiliated to a social security scheme * Breast-feeding women * OCT-A signal strength \< 7
Where it's running
-
Chu Dijon Bourogne
Dijon, France Recruiting
Study contacts
- Study coordinator: Louis ARNOULD
- Email: Louis.arnould@chu-dijon.fr
- Phone: 0380293453
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chorioretinal Imaging and Vascular Biomarkers in Ultra-Trail Runners
This study tests whether noninvasive eye imaging can reveal retinal and choroidal blood vessel changes in ultra-trail runners compared with active controls.
-
Lipid and mitochondrial clues in aortic aneurysm with bicuspid or tricuspid valves
This study tests whether inflammatory and metabolic signatures in myeloid cells and aortic tissue differ between patients with bicuspid versus tricuspid aortic valves who need surgery for ascending aortic aneurysm.
-
Value of trio genome sequencing in early-onset and atypical psychiatric disorders
This study tests whether sequencing the genomes of a patient and both biological parents can help explain early-onset or unusual psychiatric disorders in people without intellectual disability or congenital anomalies.
-
Pupillometry to predict postoperative pain after heart surgery
We’re testing whether measuring pupil responses can help predict how much pain a patient will feel after heart surgery once tubes come out and the patient can communicate.
-
BDNF Levels and Atrial Cardiomyopathy in People Having AF Ablation
This study tests whether circulating BDNF levels are linked to atrial cardiomyopathy in adults having their first ablation for persistent atrial fibrillation.
-
Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT
This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.